Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.16 USD
Change Today -0.11 / -4.85%
Volume 799.2K
As of 8:04 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Open
$2.25
Previous Close
$2.27
Day High
$2.28
Day Low
$2.14
52 Week High
10/16/14 - $8.12
52 Week Low
07/30/15 - $2.14
Market Cap
83.1M
Average Volume 10 Days
700.5K
EPS TTM
$-0.38
Shares Outstanding
38.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINIUM PHARMACEUTICALS INC (ATNM)

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products include Actimab-A, an antibody-drug construct, which includes monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct that comprises the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, and is used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its Iomab-B is in preparation for a Phase III multicenter clinical trial for bone marrow conditioning for HSCT in relapsed and refractory AML patients. The company was founded in 2000 and is based in New York, New York.

12 Employees
Last Reported Date: 03/16/15
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $442.0K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc. Advances Iomab b Towards Phase 3 with Pre ind Meeting Request

Actinium Pharmaceuticals, Inc. announced that it has submitted a request for a pre-IND (Investigative New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently preparing to commence the pivotal Phase 3 trial. During the early development of a new drug, manufacturers are required to apply for and obtain IND designation. Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fast growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Actinium Pharmaceuticals, Inc.(AMEX:ATNM) dropped from Russell 2000 Index

Actinium Pharmaceuticals, Inc. will be removed from Russell 2000 Index

Actinium Pharmaceuticals, Inc.(AMEX:ATNM) dropped from Russell 3000 Index

Actinium Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $2.16 USD -0.11

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies
 

Industry Analysis

ATNM

Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit www.actiniumpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.